We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
European regulators this week approved a complicated three-part transaction that would see Novartis and GlaxoSmithKline swapping parts of their companies and creating a consumer healthcare joint venture. Read More
Gilead has expanded its licensing agreements with eight India-based generic drugmakers to market cheaper copies of its pricey blockbuster hepatitis C therapy Sovaldi in 91 developing countries. Read More
As negotiators continue to shape the Trans-Pacific Partnership trade deal, the length of patent protection for biologics remains a sticking point with the U.S. continuing to push for 12 years of protection before a biologic drug can be copied. Read More
President Obama will ask Congress to approve more than $1.2 billion in funding — nearly double the current amount — to fuel development of new antibiotics. Read More
Actavis will become the UK’s largest generics supplier, once its roughly $461 million acquisition of Auden Mckenzie closes in the first quarter of this year. Read More
The White House released a joint statement by President Barack Obama and Indian Prime Minister Narenda Modi pledging to negotiate a harmonized approach to intellectual property protections and establish standard definitions for what is patentable. Read More
The Supreme Court wasted no time in acting on the precedent it set last week in its Copaxone ruling, sending several patent cases, including one Hatch-Waxman dispute, back to the appellate level. Read More